Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia
Status:
Unknown status
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Hyperprolactinemia is a frequent consequence of treatment with typical antipsychotic agents
and atypical antipsychotics such as risperidone. Recent studies have suggested that
aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics.
Thus, we conducted this study to evaluate the dose effects of adjunctive treatment with
aripiprazole on hyperprolactinemia in stable schizophrenic patients maintained with
risperidone.